Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis

Journal of Liver Cancer, Journal Year: 2024, Volume and Issue: 24(1), P. 81 - 91

Published: Jan. 22, 2024

Background/Aim: Atezolizumab plus bevacizumab and lenvatinib are currently available as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC). However, comparative efficacy studies still limited. This study aimed to investigate effectiveness these treatments in HCC patients with portal vein tumor thrombosis (PVTT).Methods: We retrospectively included who received either atezolizumab or systemic PVTT. Primary endpoint was overall survival (OS), secondary endpoints progressionfree (PFS) disease control rate (DCR) determined by response evaluation criteria solid tumors, version 1.1.Results: A total 52 were included: 30 22 lenvatinib. The median follow-up duration 6.4 months (interquartile range, 3.9-9.8). OS 10.8 (95% confidence interval [CI], 5.7 not estimated) 5.8 CI, 4.8 (<i>P</i>=0.26 log-rank test). There no statistically significant difference (adjusted hazard ratio [aHR], 0.71; 95% 0.34-1.49; <i>P</i>=0.37). PFS similar (<i>P</i>=0.63 test), 4.1 3.3-7.7) 4.3 2.6-5.8) (aHR, 0.93; 0.51-1.69; <i>P</i>=0.80). HRs after inverse probability weighting. DCRs 23.3% 18.2% receiving lenvatinib, respectively (<i>P</i>=0.74).Conclusion: comparable

Language: Английский

---

Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study

Investigational New Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 7, 2025

Language: Английский

---

Tumor‐infiltrating CD8⁺ T‐cell numbers and serum C‐reactive protein levels as a prognostic biomarker in hepatocellular carcinoma patients receiving atezolizumab plus bevacizumab

Hepatology Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Abstract Aim Atezolizumab plus bevacizumab is an established first‐line treatment for unresectable hepatocellular carcinoma (HCC). Our previous research identified CD8 + tumor‐infiltrating lymphocytes (TILs) as a potential biomarker predicting patient response to this therapy. However, not all HCC patients with TILs respond favorably atezolizumab and bevacizumab. Moreover, elevated serum C‐reactive protein (CRP) levels have been associated poor outcomes in treated immune checkpoint inhibitors across various cancer types. The aim of study was determine whether TIL numbers combined CRP could collectively predict the better than alone. Methods A total 46 who provided liver biopsy samples were included. tissue measured using immunohistochemistry. Results group 13 (28.3%) high low (≤0.54 mg/dl) demonstrated highest rate. Furthermore, had significantly longer median overall survival progression‐free remaining 33 patients. Multivariate analysis revealed that (HR 0.264; p = 0.037) Child–Pugh class 0.277; 0.009) improved survival. Conclusions These findings suggest combination may serve useful efficacy

Language: Английский

---

WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma

In Vivo, Journal Year: 2024, Volume and Issue: 38(6), P. 2774 - 2781

Published: Oct. 29, 2024

Tremelimumab plus durvalumab is an approved first-line therapy for advanced hepatocellular carcinoma (HCC). Previous studies identified WNT/β-catenin mutations or CD8+ tumor-infiltrating lymphocytes (TILs) as biomarkers that can predict responsiveness to immune checkpoint inhibitor in HCC. However, effectiveness of tremelimumab HCC have not been reported. This study investigated whether evaluation signaling and TILs by immunohistochemical staining tumor biopsy tissues the response patients with

Language: Английский

---

EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells

Communications Biology, Journal Year: 2024, Volume and Issue: 7(1)

Published: Dec. 19, 2024

Language: Английский

---

Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice

Cancers, Journal Year: 2023, Volume and Issue: 15(17), P. 4345 - 4345

Published: Aug. 30, 2023

In the systemic drug treatment of hepatocellular carcinoma, only tyrosine kinase inhibitor (TKI) sorafenib was available for a period. This followed by development regorafenib as second-line after sorafenib, and then lenvatinib, new TKI, proved non-inferiority to became first-line treatment. Subsequently, cabozantinib, another introduced treatment, along with ramucirumab, proven be predictive therapeutic efficacy when AFP levels are >400 ng/mL. It is an anti-VEGF receptor antibody. More recently, immune checkpoint inhibitors have become mainstay therapy can now used standard HCC. However, objective response rate these drugs currently 30% 40%, there high incidence side effects. Additionally, no practical biomarkers predict their Therefore, this review provides overview extensive research conducted on potential HCC from blood, tissue, or imaging information that in practice before its initiation.

Language: Английский

---

The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 24, 2023

Gastrointestinal (GI) cancers remain a significant global health burden, accounting for substantial number of cases and deaths. Regrettably, the inadequacy dependable biomarkers hinders precise forecasting patient prognosis selection appropriate therapeutic sequencing individuals with GI cancers, leading to suboptimal outcomes numerous patients. The intricate interplay between tumor-infiltrating lymphocytes (TILs) tumor immune microenvironment (TIME) has been shown be pivotal determinant response anti-cancer therapy consequential clinical across multitude cancer types. Therefore, assessment TILs garnered interest as promising prognostic biomarker in oncology, potential improve decision-making substantially. Moreover, recent discoveries immunotherapy have progressively changed landscape treatment significantly prolonged survival patients advanced cancers. Nonetheless, rate remains constrained within solid sufferers, even when TIL landscapes appear comparable, which calls development our understanding cellular molecular cross-talk TIME tumor. Hence, this comprehensive review encapsulates extant literature elucidating TILs’ underlying pathogenesis, significance, their relevance realm afflicted by tract Within review, we demonstrate that type, density, spatial distribution distinct subpopulations carries implications prediction responses survival. Furthermore, underscores indispensable role modulating subtypes, such those characterized microsatellite stability or programmed cell death ligand-1 expression concludes outlining future directions TIL-based personalized medicine, including integrating approaches into existing regimens developing novel strategies exploit unique properties avenue treatment.

Language: Английский

---

An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Cancer Diagnosis & Prognosis, Journal Year: 2023, Volume and Issue: 3(4), P. 468 - 474

Published: July 3, 2023

Background/Aim: Systemic chemotherapy with atezolizumab plus bevacizumab is approved for unresectable hepatocellular carcinoma (HCC). It necessary to identify probable predictive biomarkers chemotherapies. HCC rim arterial-phase enhancement (APHE) has been linked aggressive tumor activity. Patients and Methods: We studied the efficacy of using computed tomography (CT) or magnetic resonance imaging (MRI) features. In total, 51 patients who underwent CT MRI were classified by feature APHE. Results: Clinical responses evaluated, among those received bevacizumab, there 10 (19.6%) APHE 41 (80.4%) without found that had a better response than APHE, longer median progression-free survival compared (p=0.026). Furthermore, liver biopsy showed higher proportion CD8+ tumor-infiltrating lymphocytes (p<0.01). Conclusion: Rim in CT/MRI might be noninvasive biomarker predicting bevacizumab.

Language: Английский

---

Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular Carcinoma

Published: July 17, 2023

A number of agents, including immune checkpoint inhibitors, have become available for the treatment hepatocellular carcinoma (HCC). However, objective response rate these drugs is currently only 30% to 40%, with a high incidence side effects. There are also no prac-tical biomarkers predict their therapeutic Most systemic therapies HCC performed in general hospitals without research facilities. Such can perform imaging tests, like CT and MRI, as well pathological diagnosis using tumor tissue sampling im-munohistochemical staining. analyzing genomic or transcriptomic profiles difficult because limitations facilities, personnel, cost. Therefore, this review, we provide an overview wide range that has been conducted on from blood, tissue, information be used practically predicting effect before begins. For hos-pitals treat patients, recommend conducting after assessing state within much possible by collecting blood samples per-forming pre- MRI image evaluations.

Language: Английский

---

Dynamics of the neutrophil‑to‑lymphocyte ratio during lenvatinib treatment for unresectable hepatocellular carcinoma

Oncology Letters, Journal Year: 2024, Volume and Issue: 28(1)

Published: May 10, 2024

Lenvatinib is an approved therapy for advanced hepatocellular carcinoma (HCC). Recently, immune checkpoint inhibitors have been as frontline chemotherapies HCC, and the tumor microenvironment (TIME) has demonstrated to significantly affect HCC treatment. The neutrophil‑to‑lymphocyte ratio (NLR) associated with TIME, dynamics of NLR are prognosis or treatment efficacy in various cancer types. present study investigated TIME using 101 patients treated lenvatinib. Immunostaining CD8⁺ tumor‑infiltrating lymphocytes (TILs) was also performed 9 who underwent liver biopsy prior subsequent chemotherapy progression discontinuation due adverse events on lenvatinib values measured at start (SOT), after 1 month 3 months were 2.78±2.20, 2.61±1.86 2.66±2.36, respectively (P=0.733). Among no reduction initial dose, there significant difference between (2.34±0.25) that SOT (2.86±2.33) (P=0.613). In achieved a complete partial response, time best response 1.65±0.56, which lower than (2.05±0.78) (P=0.023). did not respond lenvatinib, disease 3.68±3.19, higher (2.78±1.79) (P=0.043). Overall, 5 out 6 had low TIL counts progression. Although included limited number patients, therapeutic effects These findings suggest potential immunomodulator.

Language: Английский

---